Evaxion Biotech A/S to present preclinical functional characterization data for EVX-04, an off-the-shelf AML therapeutic vaccine, at EHA 2026 Congress and plans clinical trial application submission in H2 2026.
Key takeaways
Evaxion will present new preclinical data on EVX-04 at EHA 2026 Congress in Stockholm on June 13, 2026.
EVX-04 is an AI-designed off-the-shelf vaccine targeting endogenous retroviral antigens in AML.
All 16 ERV fragments in EVX-04 elicit specific immune responses and prevent tumor growth in preclinical models.
Company plans to submit clinical trial application for EVX-04 in second half of 2026.
Presentation by Søren Vester Kofoed, Research Scientist, in Poster session PS2306.